Report: Drugs for the Elderly TOC

INTRODUCTION

STUDY GOALS AND OBJECTIVES REASONS FOR DOING THE STUDY SCOPE AND FORMAT METHODOLOGY ANALYST CREDENTIALS RELATED BCC STUDIES

Summary

Summary Table: TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, THROUGH 2007 ($ BILLIONS, %)
Summary Figure: TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, 2000-2007 ($ BILLIONS)

INDUSTRY OVERVIEW

THEORIES OF AGING BIOLOGICAL THEORIES CAUSAL THEORIES PSYCHOLOGICAL THEORIES AGING IN VARIOUS CULTURES AGE-RELATED CHANGES IN THE ELDERLY CARDIOVASCULAR SYSTEM Cardiovascular System (Continued) ENDOCRINE SYSTEM FEMALE REPRODUCTIVE SYSTEM GASTROINTESTINAL SYSTEM AND NUTRITION Gastrointestinal System and Nutrition (Continued) INTEGUMENTARY SYSTEM MUSCULOSKELETAL SYSTEM NEUROLOGICAL SYSTEM PULMONARY SYSTEM RENAL AND URINARY SYSTEM DISEASES AND CONDITIONS AFFECTING THE ELDERLY POPULATION

Table 1 MOST COMMON ILLNESSES IN THE OLDER AGE GROUP

HISTORY AND GROWTH OF THE ELDERLY DRUG MARKET

Table 2 PRESCRIPTION DRUG USE BY AGE GROUP
Table 3 AVERAGE ANNUAL PRESCRIPTION DRUG EXPENDITURES, BY AGE GROUP ($)

DRUG THERAPY IN THE ELDERLY PHARMACOKINETIC CHANGES Absorption Distribution Metabolism Excretion RATIONAL DRUG THERAPY POLYPHARMACY ADVERSE DRUG REACTIONS

Table 4 COMMONLY OBSERVED ADVERSE DRUG REACTIONS IN THE ELDERLY

NONCOMPLIANCE MEDICATION MANAGEMENT DEMOGRAPHICS, INCIDENCE, MORTALITY AGING IN AMERICA

Table 5 U.S. POPULATION ESTIMATES AND PROJECTIONS, BY AGE GROUP, FOR SPECIFIC YEARS, 1900 TO 2050 (THOUSANDS)
Figure 1 U.S. POPULATION ESTIMATES AND PROJECTIONS, BY AGE GROUP, FOR SPECIFIC YEARS, 1900-2050
Table 6 ESTIMATED U.S. POPULATION, BY AGE GROUP, THROUGH 2007 (THOUSANDS)

GENDER AND AGE

Table 7 ESTIAMTES OF EXPECTED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS, BY SEX, 2000, 2005 AND 2010 (YEARS)

U.S. GEOGRAPHIC DISTRIBUTION

Table 8 ESTIMATED U.S. ELDERLY (AGE 65 AND UP) POPULATION, BY U.S. STATE, 2000 AND 2025 (THOUSANDS)
Table 8 (CONTINUED)

MARITAL STATUS

Table 9 MARITAL STATUS OF THE 65 AND OVER AGE POPULATION BY SEX, 2001 (THOUSANDS)

ECONOMIC STATUS

Table 10 HOUSEHOLD INCOME BY SELECTED AGE GROUP, 2001 ($ THOUSANDS)
Table 11 POVERTY LEVEL OF PERSONS 65 YEARS AND OVER BY SELECTED CHARACTERISTIC, 1999 (THOUSANDS, %)

HEALTH CARE

Table 12 DEATHS OF 65 AND OVER POPULATION, BY RACE AND LEADING CAUSE, 1998
Table 13 PERCENT DISTRIBUTION OF NUMBER OF VISITS TO HEALTH CARE PROFESSIONALS BY SELECTED AGE GROUP, 1998
Table 14 HOSPITAL DISCHARGES AND DAYS OF CARE BY ELDERLY AGE GROUP, 1999 (# THOUSANDS)

LONG-TERM CARE

Table 15 POPULATION 65 YEARS AND OVER BY AGE FOR NURSING HOMES, HOME HEALTH, OR HOSPICE CARE, ESTIMATED 2000

TRENDS AFFECTING THE MARKET

PUBLIC POLICY DEVELOPMENT

INSURANCE ISSUES, MEDICARE, MANAGED CARE, HEALTH CARE FUNDING

Social, Legal, and Ethical Issues

Table 16 SELECTED RACIAL ORIGINS OF 65 YEAR AND OVER U.S. POPULATION, 2000 (THOUSANDS, %)

MASS MEDIA ATTITUDE

POLITICAL INVOLVEMENT

GENERIC DRUGS

Generic Drugs (Continued)

THE AGING NETWORK

The Aging Network (Continued)

MARKET ANALYSIS

ANTI-INFECTIVE AGENTS OVERVIEW PRODUCT DESCRIPTION Product Description (Continued) Product Description (Continued)

Table 17 SELECTED U.S. ANTI-INFECTIVE AGENT COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY
Table 17 (CONTINUED)
Table 17 (CONTINUED)

RESEARCH AND DEVELOPMENT

Table 18 U.S. ELDERLY ANTI-INFECTIVE AGENTS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE

MARKET SIZE AND GROWTH

Total Market

Table 19 TOTAL U.S. ANTI-INFECTIVE AGENT MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 2 TOTAL U.S. ANTI-INFECTIVE AGENT MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)
Table 20 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 3 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 21 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, THROUGH 2007 (%)
Figure 4 U.S. ELDERLY ANTI-INFECTIVE AGENT MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Competitive Structure And Market Share (Continued)

Table 22 U.S. ELDERLY ANTI-INFECTIVE AGENTS MARKET, COMPETITIVE MARKET SHARE, 2002 ($ MILLIONS)
Figure 5 U.S. ELDERLY ANTI-INFECTIVE AGENTS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002

CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS

OVERVIEW

Table 23 COMMON CAUSES OF CONGESTIVE HEART FAILURE

Incidence and Prevalence

Advances in Prevention and Treatment

Advances in Prevention and Treatment (Continued)

Hypercholesterolemia

Hypertension

PRODUCT DESCRIPTION

Product Description (Continued)

Table 24 SELECTED U.S. CARDIOVASCULAR DRUG AND BLOOD MODIFIERS COMPARISON, DRUGS COMMONLY USED BY THE ELDELRY
Table 24 (CONTINUED)
Table 24 (CONTINUED)

RESEARCH AND DEVELOPMENT

Table 25 U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE
Table 25 (CONTINUED)

MARKET SIZE AND GROWTH

Total Market

Table 26 TOTAL U.S. CARDIOVASCULAR DRUG AND BLOOD MODIFIER MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 6 TOTAL U.S. CARDIOVASCULAR DRUG AND BLOOD MODIFIER MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)

Total Market (Continued)

Table 27 U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 7 U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 28 U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)
Figure 8 U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 29 U.S. ELDERLY CARDIOVASULCAR DRUGS AND BLOOD MODIFIERS MARKET, COMPETITIVE MARKET SHARE, 2002 ($ MILLIONS)
Figure 9 U.S. ELDERLY CARDIOVASCULAR DRUGS AND BLOOD MODIFIERS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)

CENTRAL NERVOUS SYSTEM DRUGS

OVERVIEW

Alzheimer's Disease

Anxiety

Cerebrovascular Disease

Dementia

Depression

Table 30 DRUGS THAT MAY PRECIPITATE DEPRESSION

Epilepsy

Osteoarthritis

Osteoarthritis (Continued)

Osteoarthritis (Continued)

Parkinson's Disease

Rheumatoid Arthritis

Table 31 SELECTED U.S. CENTRAL NERVOUS SYSTEM DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY
Table 31 (CONTINUED)
Table 31 (CONTINUED)
Table 31 (CONTINUED)

RESEARCH AND DEVELOPMENT

Table 32 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE
Table 32 (CONTINUED)

MARKET SIZE AND GROWTH

Total Market

Table 33 TOTAL U.S. CENTRAL NERVOUS SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 10 TOTAL U.S. CENTRAL NERVOUS SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)
Table 34 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 11 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 35 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, THROUGH 2007 (%)
Figure 12 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Competitive Structure and Market Share (Continued)

Table 36 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Figure 13 U.S. ELDERLY CENTRAL NERVOUS SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)

DERMATOLOGIC AND SENSORY ORGAN DRUGS

OVERVIEW

PRODUCT DESCRIPTION

Product Description (Continued)

Table 37 SELECTED U.S. DERMATOLOGIC AND SENSORY ORGAN DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY
Table 37 (CONTINUED)
Table 37 (CONTINUED)

RESEARCH AND DEVELOPMENT

Table 38 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE
Table 38 (CONTINUED)

MARKET SIZE AND GROWTH

Total Market

Table 39 TOTAL U.S. DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 14 TOTAL U.S. DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)
Table 40 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 15 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 41 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)
Figure 16 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 42 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Figure 17 U.S. ELDERLY DERMATOLOGIC AND SENSORY ORGAN DRUG MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002

GASTROINTESTINAL DRUGS

OVERVIEW

PRODUCT DESCRIPTION

Product Description (Continued)

Product Description (Continued)

Table 43 SELECTED U.S. GASTROINTESTINAL DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY

RESEARCH AND DEVELOPMENT

Table 44 U.S. ELDERLY GASTROINTESTINAL DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE

MARKET SIZE AND GROWTH

Total Market

Table 45 TOTAL U.S. GASTROINTESTINAL DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 18 TOTAL U.S. GASTROINTESTINAL DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002-2007 ($ BILLIONS, %)
Table 46 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 19 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 47 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)
Figure 20 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 48 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Table 48 (CONTINUED)
Figure 21 U.S. ELDERLY GASTROINTESTINAL DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)

KIDNEY AND URINARY SYSTEM DRUGS

OVERVIEW

PRODUCT DESCRIPTION

Table 49 SELECTED U.S. KIDNEY AND URINARY SYSTEM DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY

RESEARCH AND DEVELOPMENT

Table 50 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE

MARKET SIZE AND GROWTH

Total Market

Table 51 TOTAL U.S. KIDNEY AND URINARY SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 22 TOTAL U.S. KIDNEY AND URINARY SYSTEM DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS)
Table 52 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 23 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 53 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)
Figure 24 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 54 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Figure 25 U.S. ELDERLY KIDNEY AND URINARY SYSTEM DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)

MALIGNANT AND IMMUNE DISEASE DRUGS

OVERVIEW

PRODUCT DESCRIPTION

Product Description (Continued)

Product Description (Continued)

Product Description (Continued)

Product Description (Continued)

Table 55 SELECTED U.S. MALIGNANT AND IMMUNE DISEASE DRUGS, DRUGS COMMONLY USED BY THE ELDERLY

RESEARCH AND DEVELOPMENT

Table 56 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE

MARKET SIZE AND GROWTH

Total Market

Table 57 TOTAL U.S. MALIGNANT AND IMMUNE DISEASE DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 26 TOTAL U.S. MALIGNANT AND IMMUNE DISEASE DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)
Table 58 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 27 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 59 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Figure 28 U.S. ELDERLY MALIGNANT AND IMMUNE DISEASE DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)

METABOLIC, ENDOCRINE AND HORMONE DRUGS

OVERVIEW

Osteoporosis

Diabetes

Thyroid Disorders

PRODUCT DESCRIPTION

Product Description (Continued)

Table 60 SELECTED U.S. METABOLIC, ENDOCRINE, AND HORMONE DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY

RESEARCH AND DEVELOPMENT

Table 61 U.S. ELDERLY METABOLIC, ENDOCRINE, AND HORMONE DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE

MARKET SIZE AND GROWTH

Total Market

Table 62 TOTAL U.S. METABOLIC, ENDOCRINE, AND HORMONE DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 29 TOTAL U.S. METABOLIC, ENDOCRINE, AND HORMONE DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)
Table 63 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 30 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 64 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)
Figure 31 U.S. ELDERLY METABOLIC, ENDOCRINE AND HORMONE DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 65 U.S. ELDERLY METABOLIC, ENDOCRINE, AND HORMONE DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Figure 32 U.S. ELDERLY METABOLIC, ENDOCRINE, AND HORMONE DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)

RESPIRATORY DRUGS

OVERVIEW

PRODUCT DESCRIPTION

Product Description (Continued)

Table 66 SELECTED U.S. RESPIRATORY DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY

RESEARCH AND DEVELOPMENT

Table 67 U.S. ELDERLY RESPIRATORY DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE

MARKET SIZE AND GROWTH

Total Market

Table 68 TOTAL U.S. RESPIRATORY DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 33 TOTAL U.S. RESPIRATORY DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)

Total Market (Continued)

Table 69 U.S. ELDERLY RESPIRATORY DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 34 U.S. ELDERLY RESPIRATORY DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 70 U.S. ELDERLY RESPIRATORY DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)
Figure 35 U.S. ELDERLY RESPIRATORY DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 71 U.S. ELDERLY RESPIRATORY DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Figure 36 U.S. ELDERLY RESPIRATORY DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)

SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS

OVERVIEW

PRODUCT DESCRIPTION

Table 72 SELECTED U.S. SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUG COMPARISON, DRUGS COMMONLY USED BY THE ELDERLY

RESEARCH AND DEVELOPMENT

Table 73 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS UNDER DEVELOPMENT, BY DEVELOPER AND DEVELOPMENT PHASE

MARKET SIZE AND GROWTH

Total Market

Table 74 TOTAL U.S. SEXUAL DYSFUNCTION AND GENITAL ORGAN MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, THROUGH 2007 ($ BILLIONS)
Figure 37 TOTAL U.S. SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUG MARKET BY PERCENT USAGE AND REVENUES FOR OVER AND UNDER AGE 65, 2002 AND 2007 ($ BILLIONS, %)
Table 75 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET BY PRODUCT SUB-TYPE, THROUGH 2007 ($ MILLIONS)
Figure 38 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKETS BY PRODUCT SUB-TYPE, 2000-2007 ($ MILLIONS)

Market Percent Distribution by Product Sub-type

Table 76 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2000-2007 (%)
Figure 39 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET PERCENT DISTRIBUTION BY PRODUCT SUB-TYPE, 2002 AND 2007 (%)

COMPETITIVE STRUCTURE AND MARKET SHARE

Table 77 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 ($ MILLIONS)
Figure 40 U.S. ELDERLY SEXUAL DYSFUNCTION AND GENITAL ORGAN DRUGS MARKET, COMPETITIVE MARKET SHARE BY REVENUES, 2002 (%)

MARKET

Summary

TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY

Table 78 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY BY SEGMENT, THROUGH 2007 ($ MILLIONS)
Figure 41 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY BY SEGMENT, 2002 AND 2007
Table 79 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, THROUGH 2007 ($ BILLIONS)
Figure 42 TOTAL U.S. MARKET FOR DRUGS FOR THE ELDERLY, 2002 AND 2007 (%)

TECHNOLOGY

CURRENT USES OF TECHNOLOGY

DRUG PATENT EVALUATION

Drug Patent Evaluation (Continued)

Table 80 U.S. PATENT AND EXCLUSIVITY INFORMATION BY DRUG
FOR COMMONLY USED DRUGS IN THE ELDERLY
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)
Table 80 (CONTINUED)

TECHNOLOGY PATENT EVALUATION

Table 81 EXAMPLES OF TECHNOLOGY PATENTS BENEFITING THE U.S. ELDERLY POPULATION, BY NUMBER AND COMPANY

INDUSTRY PARTICIPANTS AND COMPETITIVE ANALYSIS

Table 82 INDUSTRY PARTICIPANTS BY PRODUCT TYPE
Table 82 (CONTINUED)
Table 82 (CONTINUED)
Figure 43 INDUSTRY PARTICIPATION BY NUMBER OF SEGMENTS WITH PRODUCT PARTICIPATION
Figure 44 DISTRIBUTION OF INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT PARTICIPATION (%)
Figure 44 (CONTINUED)
Table 83 APPROVED DRUGS USED FOR THE ELDERLY BY MANUFACTURER
Table 83 (CONTINUED)
Table 83 (CONTINUED)
Table 83 (CONTINUED)

COMPANY PROFILES ABBOTT LABORATORIES, INC. ALCON LABORATORIES, INC. ALLERGAN, INC. ALZA CORP. AMGEN, INC. ASTRAZENECA PLC AVENTIS PHARMACEUTICALS, INC. BAUSCH & LOMB, INC. BAYER CORP. BOEHRINGER INGELHEIM GMBH (ROXANE LABORATORIES, INC.) ROXANE LABORATORIES, INC. BRISTOL-MYERS SQUIBB COMPANY (APOTHECON, INC., BRISTOL-MYERS SQUIBB ONCOLOGY, WESTWOOD SQUIBB) Apothecon, Inc. Bristol-Myers Squibb Oncology Westwood Squibb ELI LILLY & COMPANY FOREST LABORATORIES, INC. GLAXOSMITHKLINE PLC JOHNSON & JOHNSON (JANSSEN PHARMACEUTICA, ORTHO-MCNEIL PHARMACEUTICALS, ORTHO BIOTECH PRODUCTS) Janssen Pharmaceutica Products, L.P. Ortho-McNeil Pharmaceuticals, Inc. Ortho Biotech Products, L.P. MERCK & CO., INC. NOVARTIS PHARMACEUTICALS CORP. (NOVARTIS OPHTHALMICS, INC.) Novartis Ophthalmics, Inc. PAR PHARMACEUTICAL, INC. PFIZER, INC. Agouron Pharmaceuticals, Inc. PHARMACIA CORPORATION ROCHE GROUP (HOFFMANN-LAROCHE, INC.) Hoffmann-LaRoche, Inc. SCHERING-PLOUGH CORPORATION TAP PHARMACEUTICAL PRODUCTS, INC. WYETH

APPENDICES

Figure 45 COMPANIES MENTIONED IN THE MARKET FOR DRUGS FOR THE ELDERLY
Figure 45 (CONTINUED)

APPENDIX I: CONTACT INFORMATION FOR LEADING DRUG MANUFACTURERS ABBOTT LABORATORIES AKORN, INC. ALCON LABORATORIES, INC. ALLERGAN, INC. ALZA CORP. AMARIN PHARMACEUTICALS, INC. AMGEN, INC. APOTHECON, INC. ASTRAZENECA PLC ASTRAZENECA PHARMACEUTICALS LP ATHENA DIAGNOSTICS AVENTIS PHARMACEUTICALS, INC. BASF CORP. BAUSCH & LOMB, INC. BARR LABORATORIES, INC. BAXTER HEALTHCARE CORP. BAYER CORP. BEDFORD LABORATORIES BIOVAIL PHARMACEUTICALS, INC. (PREVIOUSLY DJ PHARMA) BRISTOL-MYERS SQUIBB ONCOLOGY BRISTOL-MYERS SQUIBB CO. CELLTECH GROUP PLC DURAMED ELAN PHARMACEUTICALS, INC. ELI LILLY & CO. ENDO PHARMACEUTICALS, INC. FIRST HORIZON PHARMACEUTICAL CORP. FLEMING & CO. FOREST LABORATORIES, INC. FUJISAWA PHARMACEUTICAL CO., LTD. GENETECH, INC. GILEAD SCIENCES, INC. GLAXOSMITHKLINE PLC HOFFMANN-LA ROCHE, INC. ICN PHARMACEUTICALS, INC. IMMUNEX CORP. JANSSEN PHARMACEUTICA PRODUCTS, L.P JOHNSON & JOHNSON JOHNSON & JOHNSON JONES PHARMA, INC. KING PHARMACEUTICALS, INC. KNOLL LABORATORIES ABBOTT LABORATORIES LIPOSOME CO., THE ELAN CORP., PLC MERCK & CO., INC. MONARCH PHARMACEUTICALS MYLAN LABORATORIES, INC. NOVARTIS PHARMACEUTICALS CORP. NOVARTIS OPHTHALMICS, INC. NOVARTIS PHARMACEUTICALS CORP. NOVO NORDISK A/S NOVO ALLÉ NOVO NORDISK PHARMACEUTICALS, INC. OCLASSEN PHARMACEUTICALS, INC. WATSON PHARMACEUTICALS, INC. ORTHO-MCNEIL PHARMACEUTICAL, INC. JOHNSON & JOHNSON ORTHO BIOTECH PRODUCTS, L.P. JOHNSON & JOHNSON PAR PHARMACEUTICAL, INC. PHARMACEUTICAL RESOURCES, INC. PFIZER, INC. PHARMACIA CORP. PURDUE PHARMA L.P. PROCTER & GAMBLE CO., THE ROXANE LABORATORIES, INC. SALIX PHARMACEUTICALS, LTD. SANKYO PHARMA, INC. SANOFI-SYNTHELABO SAVAGE LABORATORIES SCHERING-PLOUGH CORP. SCHWARZ PHARMA, INC. SIGMA-TAU, INC. SOLVAY PHARMACEUTICALS, INC. SOMERSET PHARMACEUTICALS, INC. TAP PHARMACEUTICAL PRODUCTS, INC. UCB PHARMA UNIMED PHARMACEUTICALS, INC. SOLVAY PHARMACEUTICALS, INC. UPSHER-SMITH LABORATORIES WALLACE PHARMACEUTICALS WARNER-CHILCOTT, PLC WARNER-LAMBERT PFIZER, INC. WELLSPRING PHARMACEUTICAL CORP. WESTWOOD-SQUIBB BRISTOL-MYERS SQUIBB CO. WOMEN FIRST HEALTHCARE, INC. WYETH APPENDIX II: OTHER MANUFACTURERS AND COMPANIES 3M PHARMACEUTICALS 3M CO. AAIPHARMA, INC. ABBOTT HOSPITAL PRODUCTS ABBOTT LABORATORIES ACTELION PHARMACEUTICALS U.S., INC. ADOLOR CORP. AEROPHARM TECHNOLOGY, INC. AFFERON CORP. ALEXION PHARMACEUTICALS, INC. ALLOS THERAPEUTICS, INC. AMYLIN PHARMACEUTICALS, INC. ANTEX BIOLOGICS ANTIGENICS, INC. APOTEX CORP. ARADIGM CORP. ARTECEL SCIENCES, INC. ATRIX LABORATORIES AUXILIUM PHARMACEUTICALS, INC. AVENTIS PHARMA AVENTIS AVI BIOPHARMA AXCAN PHARMA, INC. AXONYX, INC. BARR LABORATORIES, INC. BAYER AG BERLEX LABORATORIES, INC. BIONUMERIK PHARMACEUTICALS, INC. BOEHRINGER INGELHEIM GMBH BONE CARE INTERNATIONAL, INC. BOSTON LIFE SCIENCES, INC. CENTOCOR, INC. CEPHALON, INC. COLLATERAL THERAPEUTICS, INC. CORIXA CORP. CORTEX PHARMACEUTICALS, INC. CUBIST PHARMACEUTICALS, INC. CURACYTE AG CV THERAPEUTICS, INC. DEPOMED, INC. DIACRIN, INC. DIMETHAID RESEARCH, INC. DISCOVERY LABORATORIES, INC. DR. REDDY'S LABORATORIES, INC. E.I. DUPONT DE NEMOURS & CO. EISAI CO., LTD. ENDOVASC LTD., INC. FARO PHARMACEUTICALS FIRST HORIZON PHARMACEUTICAL CORP. G & W LABORATORIES, INC. GENESIS RESEARCH & DEVELOPMENT CORP., LTD. GENEVA PHARMACEUTICALS, INC. GENOME THERAPEUTICS CORP. GENZYME CORP. GUILFORD PHARMACEUTICALS, INC. HERMES BIOSCIENCES, INC. HUMAN GENOME SCIENCES, INC. ICOS CORP. IDEC PHARMACEUTICALS CORP. IMPAX LABORATORIES, INC. INHALE THERAPEUTIC SYSTEM, INC. INKINE PHARMACEUTICAL CO., INC. IMCLONE SYSTEMS, INC. INSITE VISION, INC. INSMED, INC. INDEVUS PHARMACEUTICALS, INC. ISIS PHARMACEUTICALS, INC. IVAX CORP. KYORIN PHARMACEUTICAL CO., LTD. LG CHEM, LTD. LIGAND PHARMACEUTICALS, INC. LION BIOSCIENCE, INC. MACROCHEM CORP. MCNEIL CONSUMER HEALTHCARE MEDAREX, INC. MEDICINES CO., THE MEDIGENE AG METABOLEX, INC. MILKHAUS LABORATORY, INC. MIRAVANT MEDICAL TECHNOLOGIES MONSANTO CO. MYOGEN, INC. NASTECH PHARMACEUTICAL CO., INC. NEUROBIOLOGICAL TECHNOLOGIES, INC. NEUROCRINE BIOSCIENCES, INC. NEUROGEN CORP. NEXMED, INC. NITROMED, INC. NORTHWEST BIOTHERAPEUTICS NOVEN PHARMACEUTICALS, INC. NPS PHARMACEUTICALS, INC. ORGANON, INC. ORION PHARMA PALATIN TECHNOLOGIES, INC. PHARMACEUTICAL RESOURCES, INC. PHARMACYCLICS, INC. POLYMEDICA CORP. PRAECIS PHARMACEUTICALS, INC. PROFILE THERAPEUTICS PLC PROMETHEUS LABORATORIES, INC. PROTEIN DESIGN LABS, INC. QLT, INC. ROCHE GROUP SCHERING AG SCIOS, INC. SEPRACOR, INC. SERONO LABORATORIES, INC. SHEFFIELD PHARMACEUTICALS, INC. SHIRE PHARMACEUTICALS GROUP PLC SPECTRUM PHARMACEUTICAL SUPERGEN CORP. SYN X PHARMA, INC. SYNSORB BIOTECH, INC. TAKEDA CHEMICAL INDUSTRIES, LTD. TEVA PHARMACEUTICALS USA TITAN PHARMACEUTICALS, INC. UNITED THERAPEUTICS CORP. VASOGEN, INC. VICAL, INC. VIROPHARMA, INC. VIVUS, INC. WATSON PHARMACEUTICALS, INC ZONAGEN, INC. APPENDIX III: ASSOCIATION, ORGANIZATIONS, AND UNIVERSITIES AMERICAN ASSOCIATION OF RETIRED PERSONS BAYLOR UNIVERSITY CENTER ON AN AGING SOCIETY FEDERAL TRADE COMMISION (FTC) FOOD AND DRUG ADMINISTRATION (FDA) GERONTOLOGY RESEARCH CENTER INSTITUTE FOR DIABETES DISCOVERY, THE NATIONAL COUNCIL ON THE AGING, THE (NCOA) NATIONAL INSTITUTE ON AGING (NIA) NATIONAL INSTITUTES OF HEALTH UNIVERSITY OF OKLAHOMA UNIVERSITY OF SOUTH FLORIDA UNIVERSITY OF TEXAS AT AUSTIN UNIVERSITY OF TORONTO U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES, THE U.S. PATENT AND TRADEMARK OFFICE